RESTEM to Showcase Innovative Cell Therapies at Jones Las Vegas Technology Conference

RESTEM, a Miami-based clinical-stage biotechnology company, will participate in the upcoming Jones Las Vegas Technology and Innovation Conference, presenting its advanced cell therapy research to institutional investors and technology experts. CEO Andres Isaias will deliver a virtual corporate overview on Wednesday, April 9, 2025, at 11:00 a.m. PT.

The conference, renowned for connecting innovative companies with institutional investors, provides a critical platform for emerging biotechnology firms to showcase their potential breakthrough technologies. RESTEM's presentation will focus on its two primary research programs: Restem-L, utilizing umbilical cord lining stem cells for autoimmune diseases, and natural killer cell therapeutics targeting senescence and age-associated disorders.

The company's approach represents a significant advancement in regenerative medicine, offering off-the-shelf cell therapies designed to modulate the immune system. By leveraging proprietary technologies and advanced manufacturing capabilities, RESTEM aims to develop treatments that could potentially improve patient outcomes across a broad range of disabling diseases.

Institutional investors and healthcare technology experts attending the conference will have the opportunity to learn about RESTEM's innovative research strategies and potential therapeutic applications. The virtual presentation format ensures broader accessibility for stakeholders interested in cutting-edge medical technologies.

The conference's focus on one-on-one meetings, fireside chats, and panels provides an ideal environment for RESTEM to demonstrate its scientific expertise and potential market impact. By participating in this prestigious event, the company signals its commitment to advancing medical research and developing transformative cell therapies.

RESTEM's research into umbilical cord lining stem cells and natural killer cell therapeutics represents a promising approach to addressing complex medical challenges. The company's work could potentially revolutionize treatment strategies for autoimmune conditions and age-related disorders, offering hope for patients with currently limited therapeutic options.